HCM - HUTCHMED (China) Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

HUTCHMED (China) Limited

Cheung Kong Center
48th Floor 2 Queen's Road
Hong Kong
852 2121 8200

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees1,280

Key Executives

NameTitlePayExercisedYear Born
Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBAExec. Chairman85kN/A1952
Dr. Wei-Guo Su B.Sc., Ph.D.CEO, Chief Scientific Officer & Exec. Director1.97MN/A1958
Mr. Chig Fung Cheng BEc, CACFO & Exec. Director886kN/A1967
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., MACompany Sec. & Non-Exec. DirectorN/AN/A1952
Dr. Karen Jane AtkinExec. VP & COON/AN/A1966
Mr. Kin Hung Lee M.B.A.Sr. VP of Corp. Fin. & Devel.N/AN/A1977
Mr. Charles George Rupert NixonGroup Gen. CounselN/AN/A1970
Ms. Selina ZhangSr. VP of Global HRN/AN/AN/A
Dr. Qingmei Wang Ph.D.Sr. VP of Bus. Devel. & Strategic AlliancesN/AN/A1963
Mr. Hong ChenSr. VP & Chief Commercial Officer- ChinaN/AN/A1970
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Corporate Governance

HUTCHMED (China) Limited’s ISS Governance QualityScore as of May 1, 2023 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.